Changes to the Code
H.R. 8667 · Maximizing Individual Savings for Servicemembers In Obtaining Negotiated Rx Act · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
MISSION Rx Act
In committee · step 2 of 5
10 U.S.C. § 1074g Pharmacy benefits program
2 changes the bill asks for here, 2 carried out
- Carried out:
in subsection (a)(6), by adding at the end the following new subparagraphs:
(F) Notwithstanding subparagraphs (A), (B), and (C), during any year a selected drug is covered under the Drug Price Negotiation Program established under section 1191 of the Social Security Act (42 U.S.C. 1320f), the cost-sharing amount under this subsection during a year for …
- Carried out:
in subsection (i), by adding at the end the following new paragraph:
(5) The term “selected drug” has the meaning given such term in section 1192(c) of the Social Security Act (42 U.S.C. 1320f–1(c))..
§ 1074g(a)Pharmacy Benefits.—(6)–(8)
Start of § 1074g to (a)(6)(C) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (6)(D) | (D) | (D) | ||
| Notwithstanding subparagraphs (A), (B), and (C), the Secretary may selectively waive or reduce cost-sharing amounts under this subsection for a dependent of a member of the uniformed services described in section 1074(c)(3)(B) of this title if the dependent is enrolled in the TRICARE Prime Remote program and accompanies the member to the duty assignment of the member at the expense of the Federal Government. | Notwithstanding subparagraphs (A), (B), and (C), the Secretary may selectively waive or reduce cost-sharing amounts under this subsection for a dependent of a member of the uniformed services described in section 1074(c)(3)(B) of this title if the dependent is enrolled in the TRICARE Prime Remote program and accompanies the member to the duty assignment of the member at the expense of the Federal Government. | |||
| (6)(E) | (E) | (E) | ||
| Notwithstanding subparagraphs (A), (B), and (C), the cost-sharing amount under this subsection for any prescription contraceptive on the uniform formulary provided through a retail pharmacy described in paragraph (2)(E)(ii) or through the national mail-order pharmacy program is $0. | Notwithstanding subparagraphs (A), (B), and (C), the cost-sharing amount under this subsection for any prescription contraceptive on the uniform formulary provided through a retail pharmacy described in paragraph (2)(E)(ii) or through the national mail-order pharmacy program is $0. | |||
| (6)(F) | (F) [inserted: ] | |||
| [inserted: Notwithstanding subparagraphs (A), (B), and (C), during any year a selected drug is covered under the Drug Price Negotiation Program established under section 1191 of the Social Security Act (42 U.S.C. 1320f), the cost-sharing amount under this subsection during a year for such selected drug for an eligible covered beneficiary may not exceed the cost-sharing amount paid by a Medicare beneficiary for such selected drug in that year under part D of title XVIII of that Act (42 U.S.C. 1395w–101 et seq.) pursuant to such Drug Price Negotiation Program.] | ||||
| (7) | (7) | (7) | ||
| The Secretary shall establish procedures for eligible covered beneficiaries to receive pharmaceutical agents that are not included on the uniform formulary but that are considered to be clinically necessary. Such procedures shall include peer review procedures under which the Secretary may determine that there is a clinical justification for the use of a pharmaceutical agent that is not on the uniform formulary, in which case the pharmaceutical agent shall be provided under the same terms and conditions as an agent on the uniform formulary. Such procedures shall also include an expeditious appeals process for an eligible covered beneficiary, or a network or uniformed provider on behalf of the beneficiary, to establish clinical justification for the use of a pharmaceutical agent that is not on the uniform formulary. | The Secretary shall establish procedures for eligible covered beneficiaries to receive pharmaceutical agents that are not included on the uniform formulary but that are considered to be clinically necessary. Such procedures shall include peer review procedures under which the Secretary may determine that there is a clinical justification for the use of a pharmaceutical agent that is not on the uniform formulary, in which case the pharmaceutical agent shall be provided under the same terms and conditions as an agent on the uniform formulary. Such procedures shall also include an expeditious appeals process for an eligible covered beneficiary, or a network or uniformed provider on behalf of the beneficiary, to establish clinical justification for the use of a pharmaceutical agent that is not on the uniform formulary. | |||
| (8) | (8) | (8) | ||
| In carrying out this subsection, the Secretary shall ensure that an eligible covered beneficiary may continue to receive coverage for any maintenance pharmaceutical that is not on the uniform formulary and that was prescribed for the beneficiary before October 5, 1999, and stabilized the medical condition of the beneficiary. | In carrying out this subsection, the Secretary shall ensure that an eligible covered beneficiary may continue to receive coverage for any maintenance pharmaceutical that is not on the uniform formulary and that was prescribed for the beneficiary before October 5, 1999, and stabilized the medical condition of the beneficiary. | |||
§ 1074g(i)–(j)
(a)(9)–(i)(2) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (i)(3) | (3) | (3) | ||
| The term “over-the-counter drug” means a drug that is not subject to section 503(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353(b)). | The term “over-the-counter drug” means a drug that is not subject to section 503(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353(b)). | |||
| (i)(4) | (4) | (4) | ||
| The term “prescription drug” means a drug that is subject to section 503(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353(b)). | The term “prescription drug” means a drug that is subject to section 503(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353(b)). | |||
| (i)(5) | (5) [inserted: ] | |||
| [inserted: The term “selected drug” has the meaning given such term in section 1192(c) of the Social Security Act (42 U.S.C. 1320f–1(c)).] | ||||
| (j) | (j) Regulations.— | (j) Regulations.— | ||
| The Secretary of Defense shall, after consultation with the other administering Secretaries, prescribe regulations to carry out this section. | The Secretary of Defense shall, after consultation with the other administering Secretaries, prescribe regulations to carry out this section. | |||
38 U.S.C. § 1722A Copayment for medications
1 change the bill asks for here, 1 carried out
- Carried out:
Section 1722A of title 38, United States Code, is amended by adding at the end the following new subsections:
(d) Notwithstanding subsections (a) and (b), during any year a selected drug is covered under the Drug Price Negotiation Program established under section 1191 of the Social Security Act (42 U.S.C. 1320f), the copayment amount determined under this section during a year for such …
§ 1722A(b)–(e)
Start of § 1722A to (b)(1) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (b)(2) | (2) | (2) | ||
| establish a maximum monthly and a maximum annual pharmaceutical copayment amount under subsection (a) for veterans who have multiple outpatient prescriptions. | establish a maximum monthly and a maximum annual pharmaceutical copayment amount under subsection (a) for veterans who have multiple outpatient prescriptions. | |||
| (c) | (c) | (c) | ||
| Amounts collected under this section shall be deposited in the Department of Veterans Affairs Medical Care Collections Fund. | Amounts collected under this section shall be deposited in the Department of Veterans Affairs Medical Care Collections Fund. | |||
| (d) | (d) [inserted: ] | |||
| [inserted: Notwithstanding subsections (a) and (b), during any year a selected drug is covered under the Drug Price Negotiation Program established under section 1191 of the Social Security Act (42 U.S.C. 1320f), the copayment amount determined under this section during a year for such selected drug for a veteran may not exceed the copayment amount paid by a Medicare beneficiary for such selected drug in that year under part D of title XVIII of that Act (42 U.S.C. 1395w–101 et seq.) pursuant to such Drug Price Negotiation Program.] | ||||
| (e) | (e) [inserted: ] | |||
| [inserted: In this section, the term “selected drug” has the meaning given such term in section 1192(c) of the Social Security Act (42 U.S.C. 1320f–1(c)).] | ||||
38 U.S.C. § 8126 Limitation on prices of drugs procured by Department and certain other Federal agencies
8 changes the bill asks for here, 8 carried out
- Carried out:
in paragraph (3), by striking
; and
and inserting a semicolon;
- Carried out:
in paragraph (4)(C), by striking the period and inserting
; and
; and - Carried out:
by adding at the end the following new paragraph:
(5) with respect to each selected drug of the manufacturer procured by a Federal agency, as described in subsection (b), such master agreement shall be subject to the requirements in subsection (j)..
- Carried out:
in subsection (g)(1), by striking
1992
and inserting1992, except with respect to any reference to a provision of such Act in paragraphs (7) and (8) of subsection (h) and in subsection (j)
; - Carried out:
by redesignating paragraphs (5) and (6) as paragraphs (6) and (8), respectively;
- Carried out:
by inserting after paragraph (4) the following new paragraph:
(5) The term “maximum fair price” has the meaning given such term in section 1191(c)(3) of the Social Security Act (42 U.S.C. 1320f(c)(3)).; and
- Carried out:
by inserting after paragraph (6), as redesignated by subparagraph (A), the following new paragraph:
(7) The term “selected drug” has the meaning given such term in section 1192(c) of the Social Security Act (42 U.S.C. 1320f–1(c)).; and
- Carried out:
by adding at the end the following new subsections:
(j) During any year a selected drug is covered under the Drug Price Negotiation Program established under section 1191 of the Social Security Act (42 U.S.C. 1320f), each manufacturer entering into a master agreement may not set the maximum price for such selected drug included …
§ 8126(a)–(b)
Start of § 8126 to (a)(1) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (a)(2) | (2) | (2) | ||
| with respect to each covered drug of the manufacturer procured by a Federal agency described in subsection (b) on or after January 1, 1993, that is purchased under depot contracting systems or listed on the Federal Supply Schedule, the manufacturer has entered into and has in effect a pharmaceutical pricing agreement with the Secretary (or the Federal agency involved, if the Secretary delegates to the Federal agency the authority to enter into such a pharmaceutical pricing agreement) under which the price charged during the one-year period beginning on the date on which the agreement takes effect may not exceed 76 percent of the non-Federal average manufacturer price (less the amount of any additional discount required under subsection (c)) during the one-year period ending one month before such date (or, in the case of a covered drug for which sufficient data for determining the non-Federal average manufacturer price during such period are not available, during such period as the Secretary considers appropriate), except that such price may nominally exceed such amount if found by the Secretary to be in the best interests of the Department or such Federal agencies; | with respect to each covered drug of the manufacturer procured by a Federal agency described in subsection (b) on or after January 1, 1993, that is purchased under depot contracting systems or listed on the Federal Supply Schedule, the manufacturer has entered into and has in effect a pharmaceutical pricing agreement with the Secretary (or the Federal agency involved, if the Secretary delegates to the Federal agency the authority to enter into such a pharmaceutical pricing agreement) under which the price charged during the one-year period beginning on the date on which the agreement takes effect may not exceed 76 percent of the non-Federal average manufacturer price (less the amount of any additional discount required under subsection (c)) during the one-year period ending one month before such date (or, in the case of a covered drug for which sufficient data for determining the non-Federal average manufacturer price during such period are not available, during such period as the Secretary considers appropriate), except that such price may nominally exceed such amount if found by the Secretary to be in the best interests of the Department or such Federal agencies; | |||
| (a)(3) | (3) | (3) | ||
| with respect to each covered drug of the manufacturer procured by a State home receiving funds under section 1741 of this title, the price charged may not exceed the price charged under the Federal Supply Schedule at the time the drug is procured; | with respect to each covered drug of the manufacturer procured by a State home receiving funds under section 1741 of this title, the price charged may not exceed the price charged under the Federal Supply Schedule at the time the drug is procured; | |||
| (a)(4) | (4) | (4) | ||
| unless the manufacturer meets the requirements of paragraphs (1), (2), and (3), the manufacturer may not receive payment for the purchase of drugs or biologicals from— | unless the manufacturer meets the requirements of paragraphs (1), (2), and (3), the manufacturer may not receive payment for the purchase of drugs or biologicals from— | |||
| (a)(4)(A) | (A) | (A) | ||
| a State plan under title XIX of the Social Security Act, except as authorized under section 1927(a)(3) of such Act, | a State plan under title XIX of the Social Security Act, except as authorized under section 1927(a)(3) of such Act, | |||
| (a)(4)(B) | (B) | (B) | ||
| any Federal agency described in subsection (b), or | any Federal agency described in subsection (b), or | |||
| (a)(4)(C) | (C) | (C) | ||
| any entity that receives funds under the Public Health Service Act | any entity that receives funds under the Public Health Service Act[inserted: ; and] | |||
| (a)(5) | (5) [inserted: ] | |||
| [inserted: with respect to each selected drug of the manufacturer procured by a Federal agency, as described in subsection (b), such master agreement shall be subject to the requirements in subsection (j).] | ||||
| (b) | (b) | (b) | ||
| The Federal agencies described in this subsection are as follows: | The Federal agencies described in this subsection are as follows: | |||
| (b)(1) | (1) | (1) | ||
| The Department. | The Department. | |||
§ 8126(f)–(h)
(b)(2)–(f)(1) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (f)(2) | (2) | (2) | ||
| on a quarterly basis, a list of manufacturers who have entered into master agreements under this section. | on a quarterly basis, a list of manufacturers who have entered into master agreements under this section. | |||
| (g) | (g) | (g) | ||
| (g)(1) | (1) | (1) | ||
| Any reference in this section to a provision of the Social Security Act shall be deemed to be a reference to the provision as in effect on November 4, 1992. | Any reference in this section to a provision of the Social Security Act shall be deemed to be a reference to the provision as in effect on November 4, 1992[inserted: , except with respect to any reference to a provision of such Act in paragraphs (7) and (8) of subsection (h) and in subsection (j)]. | |||
| (g)(2) | (2) | (2) | ||
| A manufacturer is deemed to meet the requirements of subsection (a) if the manufacturer establishes to the satisfaction of the Secretary that the manufacturer would comply (and has offered to comply) with the provisions of this section (as in effect immediately after the enactment of this section), and would have entered into an agreement under this section (as such section was in effect at such time), but for a legislative change in this section after November 4, 1992. | A manufacturer is deemed to meet the requirements of subsection (a) if the manufacturer establishes to the satisfaction of the Secretary that the manufacturer would comply (and has offered to comply) with the provisions of this section (as in effect immediately after the enactment of this section), and would have entered into an agreement under this section (as such section was in effect at such time), but for a legislative change in this section after November 4, 1992. | |||
| (h) | (h) | (h) | ||
| In this section: | In this section: |
§ 8126(h)–(j)
(h)(1)–(4) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (h)(4)(B) | (B) | (B) | ||
| in the packaging, repackaging, labeling, relabeling, or distribution of prescription drug products. | in the packaging, repackaging, labeling, relabeling, or distribution of prescription drug products. | |||
| (h)(4) | Such term does not include a wholesale distributor of drugs or a retail pharmacy licensed under State law. | Such term does not include a wholesale distributor of drugs or a retail pharmacy licensed under State law. | ||
| (h)(5) | (5) [inserted: ] | |||
| [inserted: The term “maximum fair price” has the meaning given such term in section 1191(c)(3) of the Social Security Act (42 U.S.C. 1320f(c)(3)).] | ||||
| (h)(6) | [inserted: (6)] | |||
| The term “non-Federal average manufacturer price” means, with respect to a covered drug and a period of time (as determined by the Secretary), the weighted average price of a single form and dosage unit of the drug that is paid by wholesalers in the United States to the manufacturer, taking into account any cash discounts or similar price reductions during that period, but not taking into account— | The term “non-Federal average manufacturer price” means, with respect to a covered drug and a period of time (as determined by the Secretary), the weighted average price of a single form and dosage unit of the drug that is paid by wholesalers in the United States to the manufacturer, taking into account any cash discounts or similar price reductions during that period, but not taking into account— | |||
| (h)(6)(A) | (A) | (A) | ||
| any prices paid by the Federal Government; or | any prices paid by the Federal Government; or | |||
| (h)(6)(B) | (B) | (B) | ||
| any prices found by the Secretary to be merely nominal in amount. | any prices found by the Secretary to be merely nominal in amount. | |||
| (h)(7) | (7) [inserted: ] | |||
| [inserted: The term “selected drug” has the meaning given such term in section 1192(c) of the Social Security Act (42 U.S.C. 1320f–1(c)).] | ||||
| (h)(8) | [inserted: (8)] | |||
| The term “weighted average price” means, with respect to a covered drug and a period of time (as determined by the Secretary) an amount equal to— | The term “weighted average price” means, with respect to a covered drug and a period of time (as determined by the Secretary) an amount equal to— | |||
| (h)(8)(A) | (A) | (A) | ||
| the sum of the products of the average price per package unit of each quantity of the drug sold during the period and the number of package units of the drug sold during the period; divided by | the sum of the products of the average price per package unit of each quantity of the drug sold during the period and the number of package units of the drug sold during the period; divided by | |||
| (h)(8)(B) | (B) | (B) | ||
| the total number of package units of the drug sold during the period. | the total number of package units of the drug sold during the period. | |||
| (i) | (i) | (i) | ||
| (i)(1) | (1) | (1) | ||
| If the Secretary modifies a multi-year contract described in subsection (d) to include a covered drug of the manufacturer that was not available for inclusion under the contract at the time the contract went into effect, the price of the drug shall be determined as follows: | If the Secretary modifies a multi-year contract described in subsection (d) to include a covered drug of the manufacturer that was not available for inclusion under the contract at the time the contract went into effect, the price of the drug shall be determined as follows: | |||
| (i)(1)(A) | (A) | (A) | ||
| For the portion of the first contract year during which the drug is so included, the price of the drug shall be determined in accordance with subsection (a)(2), except that the reference in such subsection to “the one-year period beginning on the date the agreement takes effect” shall be considered a reference to such portion of the first contract year. | For the portion of the first contract year during which the drug is so included, the price of the drug shall be determined in accordance with subsection (a)(2), except that the reference in such subsection to “the one-year period beginning on the date the agreement takes effect” shall be considered a reference to such portion of the first contract year. | |||
| (i)(1)(B) | (B) | (B) | ||
| For any subsequent contract year, the price of the drug shall be determined in accordance with subsection (d), except that each reference in such subsection to “the first year for which the contract is in effect” shall be considered a reference to the portion of the first contract year during which the drug is included under the contract. | For any subsequent contract year, the price of the drug shall be determined in accordance with subsection (d), except that each reference in such subsection to “the first year for which the contract is in effect” shall be considered a reference to the portion of the first contract year during which the drug is included under the contract. | |||
| (i)(2) | (2) | (2) | ||
| In this subsection, the term “contract year” means any one-year period for which a multi-year contract described in subsection (d) is in effect. | In this subsection, the term “contract year” means any one-year period for which a multi-year contract described in subsection (d) is in effect. | |||
| (j) | (j) [inserted: ] | |||
| [inserted: During any year a selected drug is covered under the Drug Price Negotiation Program established under section 1191 of the Social Security Act (42 U.S.C. 1320f), each manufacturer entering into a master agreement may not set the maximum price for such selected drug included in such master agreement at the time such master agreement is executed at a price exceeding the maximum fair price for such drug as set by such Drug Price Negotiation Program for the duration of such master agreement.] | ||||
42 U.S.C. § 1320f–2 Manufacturer agreements
1 change the bill asks for here, 1 carried out
- Carried out:
in section 1193(a)(4)(A), by striking
8126(h)(5)
and inserting8126(h)
; and
§ 1320f–2(a)(4)the manufacturer submits to the Secretary, in a form and manner specified…(A)–(C)
Start of § 1320f–2 to (a)(3)(B) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (4) | (4) | (4) | ||
| the manufacturer submits to the Secretary, in a form and manner specified by the Secretary, for the negotiation period for the price applicability period (and, if applicable, before any period of renegotiation pursuant to section 1320f–3(f) of this title), and for section 1320f–1(f) of this title, with respect to such drug— | the manufacturer submits to the Secretary, in a form and manner specified by the Secretary, for the negotiation period for the price applicability period (and, if applicable, before any period of renegotiation pursuant to section 1320f–3(f) of this title), and for section 1320f–1(f) of this title, with respect to such drug— | |||
| (A) | (A) | (A) | ||
| information on the non-Federal average manufacturer price (as defined in section 8126(h) | information on the non-Federal average manufacturer price (as defined in section 8126(h) of title 38) for the drug for the applicable year or period; | |||
| (B) | (B) | (B) | ||
| information that the Secretary requires to carry out the negotiation (or renegotiation process) under this part; and | information that the Secretary requires to carry out the negotiation (or renegotiation process) under this part; and | |||
| (C) | (C) | (C) | ||
| information that the Secretary requires to carry out section 1320f–1(f) of this title, including rebates under paragraph (4) of such section; and | information that the Secretary requires to carry out section 1320f–1(f) of this title, including rebates under paragraph (4) of such section; and |
Rest of § 1320f–2 unchanged
42 U.S.C. § 1320f–3 Negotiation and renegotiation process
1 change the bill asks for here, 1 carried out
- Carried out:
in section 1194(c)(6), by striking
8126(h)(5)
and inserting8126(h)
.
§ 1320f–3(c)–(e)
Start of § 1320f–3 to (c)(5)(A) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (c)(5)(B) | (B) Exclusion | (B) Exclusion | ||
| The term “long-monopoly drug” shall not include a vaccine that is licensed under section 262 of this title and marketed pursuant to such section. | The term “long-monopoly drug” shall not include a vaccine that is licensed under section 262 of this title and marketed pursuant to such section. | |||
| (c)(6) | (6) Average non-Federal average manufacturer price | (6) Average non-Federal average manufacturer price | ||
| In this part, the term “average non-Federal average manufacturer price” means the average of the non-Federal average manufacturer price (as defined in section 8126(h) | In this part, the term “average non-Federal average manufacturer price” means the average of the non-Federal average manufacturer price (as defined in section 8126(h) of title 38) for the 4 calendar quarters of the year involved. | |||
| (d) | (d) Temporary floor for small biotech drugs | (d) Temporary floor for small biotech drugs | ||
| In the case of a selected drug that is a qualifying single source drug described in section 1320f–1(d)(2) of this title and with respect to which the first initial price applicability year of the price applicability period with respect to such drug is 2029 or 2030, the maximum fair price negotiated under this section for such drug for such initial price applicability year may not be less than 66 percent of the average non-Federal average manufacturer price for such drug (as defined in subsection (c)(6)) for 2021 (or, in the case that there is not an average non-Federal average manufacturer price available for such drug for 2021, for the first full year following the market entry for such drug), increased by the percentage increase in the consumer price index for all urban consumers (all items; United States city average) from September 2021 (or December of such first full year following the market entry), as applicable, to September of the year prior to the selected drug publication date with respect to the initial price applicability year. | In the case of a selected drug that is a qualifying single source drug described in section 1320f–1(d)(2) of this title and with respect to which the first initial price applicability year of the price applicability period with respect to such drug is 2029 or 2030, the maximum fair price negotiated under this section for such drug for such initial price applicability year may not be less than 66 percent of the average non-Federal average manufacturer price for such drug (as defined in subsection (c)(6)) for 2021 (or, in the case that there is not an average non-Federal average manufacturer price available for such drug for 2021, for the first full year following the market entry for such drug), increased by the percentage increase in the consumer price index for all urban consumers (all items; United States city average) from September 2021 (or December of such first full year following the market entry), as applicable, to September of the year prior to the selected drug publication date with respect to the initial price applicability year. | |||
| (e) | (e) Factors | (e) Factors | ||
| For purposes of negotiating the maximum fair price of a selected drug under this part with the manufacturer of the drug, the Secretary shall consider the following factors, as applicable to the drug, as the basis for determining the offers and counteroffers under subsection (b) for the drug: | For purposes of negotiating the maximum fair price of a selected drug under this part with the manufacturer of the drug, the Secretary shall consider the following factors, as applicable to the drug, as the basis for determining the offers and counteroffers under subsection (b) for the drug: |
Rest of § 1320f–3 unchanged